FDA
-
-
-
-
-
-
-
Vir Biotechnology grants Norgine exclusive license for hepatitis delta treatment
-
-
-
-
-
-
-
Vir Biotechnology enrolls first patient in ECLIPSE 3 hepatitis delta trial
-
-
-
-
-
-
-
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
-
-
-
-
-
-
-
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
-
-
-
-
-
-
-
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results
-
-
-
-
-
-
-
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
-
-
-
-
-
-
-
Vir Biotechnology (VIR) PT Slashed to $45 at Needham & Company on sotrovimab Issues
-
334,268 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


